Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum Disorders

American Journal of Psychiatry, Год журнала: 2025, Номер unknown

Опубликована: Май 28, 2025

The authors sought to determine whether genetic predispositions cognitive ability or psychiatric conditions interact with anticholinergic burden (AChB) impact cognition and brain structure in individuals psychotic disorders. Participants psychosis spectrum disorders (N=1,704) from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) consortium, 18-65 years of age representing diverse ancestries, underwent assessments, structural neuroimaging, genotyping, a comprehensive medication review. primary outcome was Brief Assessment Cognition Schizophrenia (BACS) composite score, phenotype total gray matter volume. AChB scores scheduled medications were quantified using CRIDECO Anticholinergic Load Scale. Polygenic (PGSs) cognition, schizophrenia, bipolar disorder, depression constructed, PGS subsequently generated. Linear regression models used examine AChB-PGS interactions their associations outcomes, adjusting clinical covariates multiple testing false discovery rate. Hypothesis-driven moderated mediation explore potential association pathways. Higher significantly associated lower BACS performance reduced Individuals higher values exhibited greater adverse effects on BACS, while those showed more pronounced volume reductions AChB. impairment partially mediated by PGS. Anticholinergic-polygenic disorders, highlighting novel gene-by-environment interaction that advances our mechanistic understanding impairments this population.

Язык: Английский

---

Development of the Swedish anticholinergic burden scale (Swe-ABS)

BMC Geriatrics, Год журнала: 2023, Номер 23(1)

Опубликована: Авг. 25, 2023

Abstract Background Drugs with anticholinergic properties are associated cognitive adverse effects, especially in patients vulnerable to central muscarinic antagonism. A variety of drugs show weak, moderate or strong effects. Therefore, the cumulative burden should be considered impairment. This study aimed develop a Swedish Anticholinergic Burden Scale (Swe-ABS) used health care and research. Methods systematic literature review was conducted PubMed Ovid Embase identify previously published tools quantifying drug (i.e., exposure). grading scores (0–3, no high activity) were extracted from identified lists. Enteral parenteral authorized Sweden included. conflicting existing lists assessed by an expert group. Two that not also added evaluation process. Results The search following nine scales: Activity Scale, Classification, updated Cognitive scale, Drug Load Risk Clinician-rated German Korean Scale. list significant effects provided National Board Health Welfare included suggested Swe-ABS consists 104 scored as having hundred fifty-six listed based on previous scales. In total, 62 Conclusions is simplified method quantify easy use clinical practice. Publication this scale might make clinicians more aware patients’ total burden. Further research needed validate evaluate exposure versus clinically outcomes.

Язык: Английский

---

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort

European Neuropsychopharmacology, Год журнала: 2023, Номер 77, С. 67 - 79

Опубликована: Сен. 21, 2023

Язык: Английский

---

A prospective cohort study of familial versus sporadic essential tremor cases: Do clinical features evolve differently across time?

Journal of the Neurological Sciences, Год журнала: 2023, Номер 454, С. 120854 - 120854

Опубликована: Окт. 26, 2023

Язык: Английский

---

Increased anticholinergic medication use in middle‐aged and older autistic adults and its associations with self‐reported memory difficulties and cognitive decline

Autism Research, Год журнала: 2023, Номер 17(4), С. 852 - 867

Опубликована: Дек. 18, 2023

Many commonly used prescription and over-the-counter medicines have potent anticholinergic (AC) effects. Among older adults, AC medications are associated with cognitive impairment risk for disorders, including Alzheimer's disease. Collectively, the impact of is known as burden (ACB). Because high rates co-occurring medical psychiatric conditions, autistic adults may exposure and, thus, experience elevated ACB. However, no research has characterized or examined its associations outcomes in adults. Autistic (40-83 years) recruited via Simons Powering Autism Research's (SPARK) Research Match service self-reported their medication use (N = 415) memory complaints 382) at Time (T)1. At T2, 2 years later, a subset T1 participants 197) on decline cognition. Medications were coded using two scales potency. A proportion (48.2%-62.9%, depending upon potency scale) reported taking least one effects, 20.5% to 26.5% clinically-relevant levels (potency ≥3). After controlling birth-sex, age, hierarchical linear regression models showed total ACB scores values ≥3 predicted greater complaints. Logistic that follow-up later. Understanding medications-including potentially earlier polypharmacy-and impacts cognition (e.g., dementia risk) warranted.

Язык: Английский

---

Frequency of Single or Combined Anticholinergic Medication Usage as Potentially Inappropriate Medications among the Oldest-Old Age Subgroup

Psychiatry and Clinical Psychopharmacology, Год журнала: 2024, Номер 34(1), С. 43 - 49

Опубликована: Март 21, 2024

The use of medications with anticholinergic effects can have negative on older patients, such as cognitive dysfunction and falls. aim this study was to determine the frequency medication among oldest-old age group analyze factors associated its use.

Язык: Английский

---

Hospitalized Patients with Delirium and 28-Day Unplanned Hospital Readmissions: A Longitudinal Retrospective Cohort Study

Journal of the American Medical Directors Association, Год журнала: 2024, Номер 25(8), С. 105005 - 105005

Опубликована: Апрель 24, 2024

Язык: Английский

---

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Июнь 12, 2024

Aim The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess burden and yet, there is no consensus indicating which scale more relevant for patients We aimed identify valid estimating the risk iatrogenic impairment Methods identified 27 a literature review. responses neuropsychological tests 839 individuals schizophrenia or schizoaffective disorder FACE-SZ database were collected between 2010 2021. estimated association objective global scales, number psychotropic drugs, chlorpromazine lorazepam equivalents bivariable regressions cross-sectional design. then adjusted models covariates: predictors significantly multiple linear considered good concurrent validity performance. Results Eight drug impairment. most convenient predictor compute, was worse executive function (Standardized β = −0.12, p .004) reasoning −0.08, .037). Conclusion Anticholinergic burden, weakly cognition, thus suggesting that explained by factors other than medication. drugs parsimonious method

Язык: Английский

---

Effectiveness Of the Antispasmodic Pridinol Vs. Nsaids in Patients with Acute (Low) Back Pain – Results of Providence, A Retrospective, Non-Interventional Propensity- Score Matched Dual Cohort Analysis of Depersonalized 4-Week Real-World Data Provided by The German Pain E-Registry

Archives of Pharmacy & Pharmacology Research, Год журнала: 2024, Номер 4(2)

Опубликована: Март 12, 2024

Current guidelines recommend the preferred use of NSAIDs for treatment acute (low) back pain [a(L)BP] a limited period time, although their effects in controlled clinical trials is at best manageable and effect sizes questionable relevance.

Язык: Английский

---

Cumulative Dose Effects of H1 Antihistamine Use on the Risk of Dementia in Patients With Allergic Rhinitis

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2024, Номер 12(8), С. 2155 - 2165

Опубликована: Июнь 25, 2024

Язык: Английский

---